OncoMatch/Clinical Trials/NCT06205849
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
Is NCT06205849 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IRE + intratumoral mitazalimab (CD40 antibody) and NanoKnife for pancreatic cancer.
Treatment: IRE + intratumoral mitazalimab (CD40 antibody) · NanoKnife — This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, and decrease the risk of recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: NCCN-preferred chemotherapy regimen (modified FOLFIRINOX, gemcitabine + albumin-bound paclitaxel, NALIRIFOX)
A minimum of 4 months of one of the chemotherapy regimens preferred by the NCCN for good performance status patients (currently modified FOLFIRINOX, gemcitabine + albumin-bound paclitaxel, or NALIRIFOX)
Cannot have received: CD40 antibody
Prior treatment with a CD40 antibody
Cannot have received: radiation therapy
Exception: to the pancreas
Prior receipt of radiation therapy to the pancreas
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5x10^9/L; Platelets ≥ 100x10^9/L; Hemoglobin ≥9 g/dL
Kidney function
Serum creatinine ≤1.5 x ULN OR creatinine clearance ≥40 mL/min (as calculated by Modified Cockcroft-Gault formula)
Liver function
Serum total bilirubin ≤ 1.5 X ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN
Have adequate organ function per criteria below: * Absolute neutrophil count (ANC) ≥ 1.5x109/L * Platelets ≥ 100x109/L * Hemoglobin ≥9 g/dL * Serum creatinine ≤1.5 x ULN OR creatinine clearance ≥40 mL/min (as calculated by Modified Cockcroft-Gault formula) * Serum total bilirubin ≤ 1.5 X ULN * AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSD Moores Cancer Center · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify